Prognosis in Malignant Melanoma.

Gleave, HumphreyH.

doi:10.1016/s0140-6736(01)04247-7

Cited by 11 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High percentage cure rates were obtained in this material (Table IV) as compared with previous reports fromother clinics (1,3,4,9,10,13,28,37,47,54,60); the conventional &year cure rate amounts to more than 34.6 per cent (uncorrected), and the late end result up t o 1948 is 30.8 per cent (uncorrected), The over-all &year survival rate was 9.7 No significant differences in cure rates can be claimed with reference to the various adult age groups (Table VII), nor are there any sex differences. The end results at 1948 in relation to primary site of melanoma are listed in Table VIII.…”

Section: Report and Evaluation Of Resultssupporting

confidence: 78%

Malignant Melanoma of the Skin: Report of 341 Cases Treated during the Years 1929-1943

Sylvén¹

1949

Acta Radiologica

View full text Add to dashboard Cite

Section: Report and Evaluation Of Resultssupporting

confidence: 78%

Malignant Melanoma of the Skin: Report of 341 Cases Treated during the Years 1929-1943

Sylvén¹

1949

Acta Radiologica

View full text Add to dashboard Cite

“…High percentage cure rates were obtained in this material (Table IV) as compared with previous reports fromother clinics (1,3,4,9,10,13,28,37,47,54,60); the conventional 5-year cure rate amounts to more than 34.6 per cent (uncorrected), and the late end result up to 1948 is 30.8 per cent (uncorrected). The over-all 5-year survival rate was 9.7 I II III I II III I II III I II III I II 56 No significant differences in cure rates can be claimed with reference to the various adult age groups (Table VII), nor are there any sex differ ences.…”

Section: Report and Evaluation Of Resultssupporting

confidence: 66%

“…Present methods have salvaged 5 cases only in our series (Table XI) With a view to improvement of cure rate in Stage I melanomas it seems thus advisable to join previous authors (1,9,25,28,33,34,45,(52)(53)(54)66) in recommending prophylactic gland dissection in all suitable cases. 1 Before leaving the prophylactic gland dissection it should be emphasized that this method is not applicable to melanoma situated »in the midline of the face or chest for which a bilateral neck dissection or a bilateral axillary dissection would have to be carried out» (1).…”

Section: Discussioumentioning

confidence: 70%

“…More patients will evidently be salvaged by too wide excisions than by inadequate or repeated operations. We hope that in suitable cases ex cision and dissection »in continuity» for melanoma, as advocated by the Memorial Hospital Group (52)(53)(54)(55)(56), and further the »prophylactic» dissection of regional glands (1,9,25,28,33,34,45,(52)(53)(54)66) will provide more cures than previously used methods have given.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Malignant Melanoma of the Skin: Report of 341 Cases Treated during the Years 1929-1943

Sylven¹

1949

Acta Radiologica

View full text Add to dashboard Cite

Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms

Haupt

Mann

Trump

et al. 1984

Cancer

132

102

View full text Add to dashboard Cite

Metastatic carcinoma to the testis is unusual. There are only seven previously reported cases in which a testicular mass was the first clinical manifestation of an underlying malignancy. The authors review 127 cases in which the testis was involved by metastatic carcinoma, and describe an additional two patients in whom a malignant testicular mass was the presenting sign of an underlying nontesticular carcinoma. The tumors most commonly reported to metastasize to the testis are: prostate (45 cases), lung (25 cases), melanoma (12 cases), colon (11 cases), kidney (10 cases), stomach (6 cases), and pancreas (5 cases). Neuroblastoma, retinoblastoma, carcinoid tumor, and cancers of the bile duct, ureter, bladder, salivary gland, and thyroid have also involved the testis secondarily. Nineteen patients (15%) had bilateral testicular metastases. Patients with secondary testicular neoplasms were older in general than those with germ cell tumors (mean, 55 years; median, 57 years). Histologically, the presence of extensive lymphatic and vascular invasion and an interstitial pattern, in which the seminiferous tubules are spared, is suggestive of a metastasis. In four of the nine cases (44%) in which testicular enlargement was the first manifestation of an underlying carcinoma the correct pathologic diagnosis was initially missed. Serum alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) are occasionally elevated in patients with nontesticular primary tumors, but markedly elevated levels in young patients suggest a nonseminomatous germ cell tumor, as does positive immunoperoxidase staining for AFP and HCG.Cancer 54:709-714, 1984.ERM CELL TUMORS are the most common testicular G neoplasms'** and should be the primary diagnostic consideration in young patients who present with a solitary testicular mass. However, the testes may also be the site of metastatic di~ease.~-~' When an occult malignancy first becomes manifest as a testicular mass, its distinction from a primary testicular tumor may be difficult. We report two patients who presented with testicular metastases from clinically occult primary neoplasms; the clinical features of one patient have been previously reported. 44 We review the literature regarding testicular metastases and emphasize the clinical and pathologic differences between primary and secondary testicular neoplasms.

show abstract

Prognosis in Malignant Melanoma.

Cited by 11 publications

References 1 publication

Malignant Melanoma of the Skin: Report of 341 Cases Treated during the Years 1929-1943

Malignant Melanoma of the Skin: Report of 341 Cases Treated during the Years 1929-1943

Malignant Melanoma of the Skin: Report of 341 Cases Treated during the Years 1929-1943

Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms

Contact Info

Product

Resources

About